title: A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer. EORTC-GU Group protocol 30867.
authors.affiliation: Norwegian Radium Hospital, Oslo, Norway.
authors.forename: S D
authors.initials: SD
authors.lastname: Fosså
authors.forename: T
authors.initials: T
authors.lastname: Splinter
authors.forename: K J
authors.initials: KJ
authors.lastname: Roozendaal
authors.forename: K H
authors.initials: KH
authors.lastname: Veenhof
authors.forename: M
authors.initials: M
authors.lastname: Pavone-Macaluso
authors.forename: A
authors.initials: A
authors.lastname: Calciati
authors.forename: M
authors.initials: M
authors.lastname: de Pauw
authors.forename: R
authors.initials: R
authors.lastname: Sylvester
mesh_terms: D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D015251:Epirubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D013921:Thrombocytopenia / Q000139:chemically induced; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D015251:Epirubicin